Riboflavine and severe lactic acidosis

Lancet

Volumn 353, Issue 9156, 1999, Pages 901-902

  Luzzati, Roberto ^a   Del Bravo, Paola ^a   Di Perri, Giovanni ^a   Luzzani, Aldo ^a   Concia, Ercole ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; RIBOFLAVIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; ARTERIAL PH; ARTICLE; CASE REPORT; FATTY LIVER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; ORAL DRUG ADMINISTRATION; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RIBOFLAVIN DEFICIENCY;

EID: 0033551020     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)00523-1     Document Type: Article

References (5)

1. Brinkman K, ter Hofstede HJM, Burger D, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-44.
2. Sundar K, Suarez M, Banogon P, Shapiro JM. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit Care Med 1997; 25: 1425-30.
3. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 1998; 352: 291-92.
4. Mizcock BA, Falck JL. Lactic acidosis in critical illness. Crit Care Med 1992; 20: 80-93.
5. Vir SC, Love AH, Thompson W. Riboflavin status during pregnancy. Am J Clin Nutr 1981; 34: 2699-705.